[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurobehavioral-manifestations\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurobehavioral-manifestations":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,56,115,155,192,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100472474","rett-syndrome-registry-100472474",false,"NCT05432349","Rett Syndrome Registry","Rett Syndrome Real World Data Observational Registry","RSR","Inclusion Criteria:\n\n* Male or female with a pathologic loss of function alteration of MECP2\n\nExclusion Criteria:\n\n* Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication","ALL","0 Years","99 Years",{"count":21,"type":22},3000,"ESTIMATED","5 Years","OBSERVATIONAL","The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.",[27,28,29,30,31,32,33,34,35,36],"Rett Syndrome","Rett Syndrome, Atypical","Genetic Disease","Genetic Diseases, X-Linked","Intellectual Disability","Neurobehavioral Manifestations","Neurologic Manifestations","Neurologic Disorder","Neurodevelopmental Disorders","Nervous System Diseases",[38,39,40,41,42],"Rett syndrome","MECP2","Neurodevelopmental disorder","Registry","Natural History Study","RECRUITING","2026-06-26",{"date":46,"type":47},"2026-06-30","ACTUAL",{"date":49,"type":47},"2022-08-02",{"date":51,"type":22},"2028-07",{"name":53,"class":54},"International Rett Syndrome Foundation","OTHER",19,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":68,"studyType":24,"phases":4,"briefSummary":69,"conditions":70,"keywords":83,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100640521","neurofinance-human-stress-trial-during-financial-and-informational-volatility-100640521","NCT07622589","NeuroFinance Human Stress Trial During Financial and Informational Volatility","NeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST)","NFHST","Inclusion Criteria:\n\n* Adults age 18 years and older.\n* Ability to provide informed consent.\n* Willingness and ability to comply with study procedures and remote monitoring requirements.\n* Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation.\n* Willingness to utilize wearable physiologic monitoring technologies during the study period.\n* Participants with varying degrees of financial market exposure, occupational stress exposure, or digital media exposure are eligible.\n* Healthy volunteers and participants with self-reported stress-related symptoms may be enrolled.\n* Ability to read and understand English-language consent and study materials.\n\nExclusion Criteria:\n\n* Individuals unable or unwilling to provide informed consent.\n* Individuals unable to comply with remote monitoring procedures or wearable device usage requirements.\n* Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity.\n* Current incarceration or institutionalization limiting voluntary participation.\n* Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes.\n* Any condition that would significantly impair safe study participation as determined by the study investigators.",true,"18 Years",{"count":67,"type":22},2500,"24 Months","The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.",[71,72,73,74,75,76,77,78,79,80,81,82,32],"Psychological Stress","Anxiety","Emotional Stress","Autonomic Nervous System Dysfunction","Sleep Disturbance","Insomnia","Behavioral Health","Cognitive Fatigue","Occupational Stress","Financial Stress","Burnout Syndrome","Heart Rate Variability",[84,85,86,87,88,89,82,90,91,92,93,94,95,96,97,98,99,100,101,102],"NeuroFinance","Financial Stress Medicine","Wearable Biosensors","Artificial Intelligence","Machine Learning","Digital Biomarkers","Sleep Monitoring","Behavioral Analytics","Cardiovascular Telemetry","Decentralized Clinical Trial","Emotional Resilience","Physiologic Stress","Market Volatility","Economic Uncertainty","Social Media Exposure","Cognitive Performance","Stress Forecasting","Precision Wellness","Remote Patient Monitoring","NOT_YET_RECRUITING","2026-05-27",{"date":106,"type":47},"2026-06-03",{"date":108,"type":22},"2026-07-15",{"date":110,"type":22},"2029-06-30",{"name":112,"class":113},"Truway Health, Inc.","INDUSTRY",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100384702","phase-4-cognitive-outcomes-after-dexmedetomidine-sedation-in-cardiac-surgery-patients-100384702","NCT04289142","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial","CODEX","Inclusion Criteria:\n\n* Planned CABG (+\u002F- valve, including off-pump) or valve replacement via sternotomy\u002Fthoracotomy, with initial recovery in the Cardiovascular Intensive Care Unit (CVICU)\n* Age ≥60\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Pre-operative major cognitive dysfunction (CogState Brief Battery score \\\u003C 80) at screening\n* Aortic arch replacement\u002Fre-implantation (surgery requiring hypothermic circulatory arrest, e.g. Bentall procedure)\n* Allergy\u002Fcontraindication to dexmedetomidine (untreated 2nd degree type 2 or 3rd degree heart block (pacemaker), cirrhosis, HR \\\u003C 50 , grade 4 LV, renal failure or on renal replacement therapy)\n* Unlikely to comply with study assessments (e.g. no fixed address, cannot complete cognitive tests at the 3, 6, and 12 month time points)","60 Years",{"count":125,"type":22},2400,"INTERVENTIONAL",[128],"PHASE4","Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.",[131,132,133,134,135,136,32,33,36,137,138,139,140,141,142,143,144],"Delirium","Cognitive Dysfunction","Cognition Disorder","Neurocognitive Disorders","Mental Disorders","Confusion","Signs and Symptoms","Dexmedetomidine","Hypnotics and Sedatives","Central Nervous System Depressants","Physiological Effects of Drugs","Analgesics, Non-Narcotic","Analgesics","Molecular Mechanisms of Pharmacological Action","2025-11-27",{"date":147,"type":47},"2025-12-01",{"date":149,"type":47},"2019-12-01",{"date":151,"type":22},"2029-03",{"name":153,"class":54},"Sunnybrook Health Sciences Centre",8,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":64,"sex":17,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":126,"phases":166,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100546572","napbiome-targeting-gut-microbiota-and-sleep-rhythm-to-improve-developmental-and-behavioral-outcomes-in-early-childhood-100546572","NCT06396689","NapBiome: Targeting Gut Microbiota and Sleep Rhythm to Improve Developmental and Behavioral Outcomes in Early Childhood","NapBiome","Inclusion Criteria:\n\nPreterm-arm:\n\n* neonates born between a gestational age of 34 0\u002F7 to 36 6\u002F7 weeks\n* partially breast-fed at the time of inclusion\n\nTerm-arm\n\n* neonates born at a gestational age of ≥ 37 0\u002F7 weeks Infants need to be\n* partially breast-fed at the time of inclusion\n\nExclusion Criteria:\n\nInfants who\n\n* receive probiotics outside the trial design\n* have a birth weight \\\u003C 1500 g\n* were prenatally drug-exposed (cannabis, cocaine, heroin, opiates, and alcohol)\n* have suspected or confirmed immunodeficiency\n* have an underlying disease (excluding transient conditions such as alimentation problems, hyperbilirubinemia, hypoglycaemia, anemia, respiratory distress syndrome or apnea-bradycardia syndrome), congenital malformations, central nervous system disease or injury or congenital infections","0 Days","7 Days",{"count":165,"type":22},380,[167],"NA","The gut-brain axis plays a crucial role in the regulation and development of psychological and physical processes. The first year of life is a critical period for the development of the gut microbiome, which parallels important milestones in establishing sleep rhythm and neurodevelopment. Growing evidence suggests that the gut microbiome influences sleep, cognition, and early neurodevelopment. For term and preterm-born infants, difficulties in sleep regulation can have major consequences on infants' health, attachment between infants and their caregivers, and can even lead to life-threatening consequences such as shaken-baby syndrome. Preterm born infants are at even higher risk for sleep and neurodevelopmental problems. Although neonatal care has improved over recent decades, preterm birth rates continue to rise and lead to a wide range of neurodevelopmental disabilities that are unaddressed with current therapies. Given the importance of sleep and the gut microbiome for brain maturation, neurodevelopment, and behavior, identifying effective interventions within the gut-brain axis at the beginning of life is likely to have long-term implications for health and development of at-risk infants.\n\nThe aims of this project are to I) demonstrate the association between the gut microbiome, sleep patterns and health outcomes in children up to two years of age; and II) to leverage gut microbiome-brain-sleep interactions to develop new intervention strategies for at-risk infants. The investigators hypothesize that the establishment of a healthy gut microbiome during early life is crucial for both short- and long-term child health outcomes, as dysbiosis can harm sleep regulation, brain maturation, and neurobehavioral development. The investigators predict that the administration of synbiotics improves microbiota establishment, sleep rhythm, and neurodevelopmental outcomes.\n\nThis project integrates a randomized controlled trial (RCT), ex vivo, and in silico experiments with I) key technology platforms for computational modeling to capture the ontogenic norms of gut microbiota; II) neuronal and actimetry-based quantification of multidimensional aspects of infant sleep; III) breath metabolomics (exhalomics) of host and microbiome metabolism; and IV) high-throughput ex vivo models for investigating host-microbiome interactions. Outcomes include I) an understanding of age-normative microbiome composition, its variation (circadian, inter-individual), and the factors that influence the microbiome's plasticity throughout infancy; II) actionable knowledge of microbial species and metabolism that can be targeted to modify sleep regulation and improve neurodevelopmental outcomes, especially in at-risk infants (e.g., preterm-born); III) microbial and metabolic biomarkers with diagnostic potential for later regulatory and behavioral problems; and IV) an open-source analytical \"toolbox\" for microbial multi-omics that can be immediately applied in other areas of microbiome-host research. To achieve these goals, our strategy combines multiple disciplines focusing on factors that exert the greatest influence on health during infancy: the gut microbiome, sleep regulation, and neurodevelopment.\n\nThe impact of this project is substantial and globally relevant, as it advances possible treatment options for supporting neurodevelopmental health in preterm- and term-born infants, explores novel translational approaches for addressing regulatory difficulties, and provides key information for tailored prophylactic synbiotics and possible development of \"post-biotics\". Further, the study supports the investigation of biomarkers for neurodevelopment and advances early prevention of developmental and mental illnesses.",[170,32],"Sleep Problem",[172,173,174,175,176,177,178,179,180,181],"microbiome","infant","gut","metagenomics","development","metabolics","pre-term","probiotics","synbiotics","brain-gut","2025-02-17",{"date":184,"type":47},"2025-02-20",{"date":186,"type":22},"2025-03-01",{"date":188,"type":22},"2029-02-28",{"name":190,"class":54},"Petra Zimmermann",2,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":114},"100566966","impact-of-iron-deficiency-anemia-on-neurobehavioral-and-cognitive-development-in-children-aged-6-to-24-months-100566966","NCT06662045","Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months","Study on the Association Between Iron Deficiency Anemia and Neurobehavioral Development and Cognitive Function in Children Aged 6 to 24 Months","Inclusion Criteria:\n\n* Children aged 6 to 24 months at the time of enrollment\n* Diagnosed with iron-deficiency anemia (for the exposure group) or confirmed\n* non-anemic status (for the control group) based on blood test results\n* Resident in the study area for at least 6 months prior to enrollment\n* Availability of parental or guardian consent to participate in the study and willingness to follow study protocols\n* Completion of all baseline assessments, including neurodevelopmental and physical growth evaluations\n\nExclusion Criteria:\n\n* Presence of congenital or chronic illnesses that could affect\n* neurodevelopment, such as Down syndrome or cerebral palsy.\n* History of severe infections or trauma within 3 months prior to enrollment that\n* could influence neurodevelopmental outcomes\n* Current use of medications or treatments that may interfere with iron metabolism (e.g., iron supplementation or blood transfusions in the last 6 months)\n* Premature birth (before 37 weeks of gestation) or low birth weight (\\\u003C 2,500 grams)\n* Parental refusal to provide consent or non-compliance with study procedures.","6 Months","6 Years",{"count":202,"type":22},1000,"The goal of this observational study is to explore the relationship between iron-deficiency anemia and neurobehavioral development in children aged 6-24 months. This study focuses on children who undergo health check-ups and blood tests at pediatric health clinics in Pingshan District, Shenzhen, China.\n\nThe main questions it aims to answer are:\n\nHow does iron-deficiency anemia affect children's neurobehavioral development, including motor skills, language ability, and social behavior? How does anemia influence growth and nutrition, such as weight, height, and body mass index (BMI) in children?\n\nParticipants will:\n\nUndergo blood tests (including hemoglobin levels, serum ferritin, and serum iron) to assess anemia status.\n\nBe assessed using the \"Neuropsychological Behavioral Development Scale for Children Aged 0-6\" to measure motor, cognitive, language, and social development.\n\nProvide general health information, such as birth history, feeding methods, and parental details, through interviews with trained surveyors.\n\nResearchers will compare children with and without iron-deficiency anemia to determine differences in neurobehavioral outcomes and development levels. The findings aim to provide evidence for early interventions to prevent the negative impacts of anemia and support children's healthy development.",[205,32,206,207],"Iron-Deficiency Anemia","Growth Disorders","Nutritional Status","2024-10-25",{"date":210,"type":47},"2024-10-28",{"date":212,"type":47},"2024-01-01",{"date":214,"type":22},"2027-06-30",{"name":216,"class":54},"Pingshan District Maternal & Child Healthcare Hospital of Shenzhen",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":229,"conditions":230,"keywords":235,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":191},"100302839","squed-series-281-home-use-and-treatment-of-autowave-reverberator-of-autism-100302839","NCT03222375","SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism","The Home-Use of Semiconducting QUantum Excitonic Device: Image Converter\u002FSound Converter\u002FElectromagnetic Converter to Improve Communicative Efforts, Speech, Language and Related Cognitive Functions in Children With Autism","SQUED™","Inclusion Criteria:\n\n* Clinical diagnosis of autism or related conditions.\n* History of Late complications at Natal Trauma:\n\n  1. Cerebral level of Natal Trauma - brain injury;\n  2. Cervical level of Natal Trauma - injury of vertebral;\n  3. Cerebral anoxia.\n* Identified language deficit(s) and\u002For other cognitive or behavioral impairments (which will be specific to each sub-study).\n* Adequate ability to perform the research tasks set for the Age level:\n\n  1. Infant - greater than 1 month to 2 years of age;\n  2. Child - greater than 2 to 12 years of age;\n  3. Adolescent - greater than 12 through 21 years of age.\n* Presence on the Skin of the interruption of Autowave front (interruption of hair separatrix - dorsal\u002Fventral) and\u002For of the Autowave Reverberators:\n\n  1. Photo of Spiral Autowaves, generated by the kernel of Autowave Reverberator - the kernel having an excitation \"tongue\";\n  2. Graphics on tracing paper of Spiral Autowaves, generated by the kernel of Autowave Reverberator - the kernel having an excitation \"tongue\".\n* Presence of Clinical protocol CRF-SQUED™:\n\n  1. Diagnostics of Autowave reverberators and Nonlinear Control of Autowave reverberators in Active media (Autowave interaction of patient - Algorithmic approach);\n  2. Mathematical Modeling of Autowave Reverberator and Computational Simulation of the treatment code (Trade Secret), and creation Active medium SQUED™ for a patient;\n  3. Recording for a patient of treatment code (Trade Secret) - Autowave regime: Hysteresis of Spiral Autowaves; Drift of Spiral Autowaves; Annihilation of Autowave reverberator.\n* Magnetogram of region of Home-use and Geographic coordinates of Home-use.\n\nExclusion Criteria:\n\n* Peripheral blindness - precludes use of Image converter SQUED™ (iSQUED™).\n* Peripheral deafness - precludes use of Sound converter SQUED™ (sSQUED™).\n* Any implanted metal device - precludes use of Electromagnetic converter SQUED™ (eSQUED™).\n* Any implanted cardiac pacemaker - precludes use of Electromagnetic converter SQUED™ (eSQUED™).","1 Month","21 Years",{"count":228,"type":22},80,"Locomotor, transport and information functions in human body systems are carried out by active media in autowave regimes! Any living organism is a (micro-macro-mega) hierarchy of autowave subsystems-an ensemble of loosely coupled subsystems of a simpler structure. From the highest levels of the hierarchy, Autowave Codes-Signals arrive, which determine the transitions of subsystems from one autowave regime to another Autowave interaction (of Complex Coherent Action). Autowave interaction is a process associated with the evolution and interaction of spatial and wave structures in the active media of the organism.\n\nChaos in organism functioning tells about health. Periodicity - Autowave reverberator may presage a disease - Autism Spectrum Disorder; Chaotic nature of oscillations in active media of physiological systems is more optimal for their vital functions than periodic one. Firstly, systems that function in chaotic regimes, can re-arrange themselves faster and easier in case of change of environmental conditions, i.e. the so called adaptive control is more easily implemented in them. Secondly, \"spreading\" of oscillations strength along comparatively wide frequency band takes place in chaotic regime.\n\nWhen an organism is young and healthy, physiological systems show the elements of chaotic behavior, i.e. irregularity and chaotic dynamics are the extremely important characteristics of health. Decrease in changeability and appearance of stable periodicity of Autowave reverberator are often connected with Autism.\n\nThe main purpose is to study brain plasticity (the changes that occur in the brain through Autowave reverberator) in children with autism. Research suggests that during development, the brains of children may change in response to their Autowave reverberator differently than the brains of typically developing individuals. Investigators want to understand why and how this difference may contribute to the symptoms of autism spectrum disorder (ASD). In this study, the investigators will be examining the effects of non-invasive neuromodulation SQUED™ series 28.1 home-use for Treatment of Autowave reverberator of Autism.\n\nIntegrative Team World Organization of Medical Synergetics (WOMS) - collaborations between physicians and researchers with expertise in biostatistics, physics, mathematics, engineering, and computer science.",[231,232,233,35,135,234,32,36],"Autistic Disorder","Autism Spectrum Disorder","Child Development Disorders, Pervasive","Asperger's Syndrome",[236,237,238,239,240,241,242,243,244,245,246,247,248],"Yaroshuk's MEGA-DISCOVERY · DIAGNOSTICS · TREATMENT","Yaroshuk's Scientific Medical School","Center of Synergetics","Controlling spatiotemporal chaos\u002FDr. Synergetic","Autowave processes in Medicine","Autowave Reverberator","Bifurcation of Dynamic systems on a plane","Spiral Autowaves","Drift of Spiral Autowaves","Excitable medium and Cellular Automata","Stochastic Resonance and Coherence Resonance","Autowaves\u002FSQUED","Theory of Semiconducting QUantum Excitonic Device","2017-11-24",{"date":251,"type":47},"2017-11-28",{"date":253,"type":47},"2017-09-26",{"date":255,"type":22},"2027-12",{"name":257,"class":54},"American Federation of Medical Synergetics"]